Search Results - "Sigurjonsdottir, Gudbjörg"

Comparison of SP142 and 22C3 PD-L1 assays in a population-based cohort of triple-negative breast cancer patients in the context of their clinically established scoring algorithms by Sigurjonsdottir, Gudbjörg, De Marchi, Tommaso, Ehinger, Anna, Hartman, Johan, Bosch, Ana, Staaf, Johan, Killander, Fredrika, Niméus, Emma

“…Background Immunohistochemical (IHC) PD-L1 expression is commonly employed as predictive biomarker for checkpoint inhibitors in triple-negative breast cancer…”
Get full text

Association of BRCA2 K3326 With Small Cell Lung Cancer and Squamous Cell Cancer of the Skin by Rafnar, Thorunn, Sigurjonsdottir, Gudbjorg R, Stacey, Simon N, Halldorsson, Gisli, Sulem, Patrick, Pardo, Luba M, Helgason, Hannes, Sigurdsson, Stefan T, Gudjonsson, Thorkell, Tryggvadottir, Laufey, Olafsdottir, Gudridur H, Jonasson, Jon G, Alexiusdottir, Kristin, Sigurdsson, Asgeir, Gudmundsson, Julius, Saemundsdottir, Jona, Sigurdsson, Jon K, Johannsdottir, Hrefna, Uitterlinden, Andre, Vermeulen, Sita H, Galesloot, Tessel E, Allain, Dawn C, Lacko, Martin, Sigurgeirsson, Bardur, Thorisdottir, Kristin, Johannsson, Oskar T, Sigurdsson, Fridbjorn, Ragnarsson, Gunnar B, Isaksson, Helgi, Hardardottir, Hronn, Gudbjartsson, Tomas, Gudbjartsson, Daniel F, Masson, Gisli, Kiemeney, Lambertus A M L, Ewart Toland, Amanda, Nijsten, Tamar, Peters, Wilbert H M, Olafsson, Jon H, Jonsson, Steinn, Thorsteinsdottir, Unnur, Thorleifsson, Gudmar, Stefansson, Kari

“…Most pathogenic mutations in the BRCA2 gene carry a high risk of hereditary breast and ovarian cancer (HBOC). However, a stop-gain mutation, K3326*…”
Get full text